Pediatric Neuromyelitis Optica Spectrum Disorder

Area of Science:

• Neurology
• Immunology
• Pediatrics

Background:

• Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe demyelinating autoimmune disease.
• It is characterized by astrocytopathy, often involving antibodies against the aquaporin-4 (AQP4) water channel.
• Pediatric NMOSD is rare, representing 3-5% of cases, and is more common in individuals of Black or East Asian ancestry.

Purpose of the Study:

• To summarize the key aspects of pediatric Neuromyelitis Optica Spectrum Disorder.
• To highlight the clinical presentation, diagnostic markers, and treatment options for NMOSD in children.
• To underscore the long-term disability risks associated with pediatric NMOSD.

Main Methods:

• Review of existing literature on pediatric NMOSD.
• Analysis of core clinical syndromes and diagnostic criteria.
• Evaluation of current and emerging therapeutic strategies.

Main Results:

• Pediatric NMOSD presents with syndromes including optic neuritis, myelitis, and brainstem/diencephalic involvement.
• Aquaporin-4 IgG (AQP4-IgG) seropositivity is a key diagnostic marker.
• First-line treatments include rituximab, azathioprine, and mycophenolate mofetil.

Conclusions:

• Pediatric NMOSD carries a high risk of permanent visual and motor disability, affecting over 50% of AQP4-IgG seropositive children.
• While novel adult therapies are emerging, pediatric treatment focuses on established immunosuppressants.
• Further research into pediatric-specific NMOSD treatments is warranted.